Celularity Inc (CELU) stock
Close on Nov 11, 2026Market cap $24.37MP/E –Yield –
Celularity Inc saw revenue fall 58.1% to $18.67M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $24.37M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $24.37M
- P/E ratio
- –
- Price to sales
- 1.31
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $18.67M
- Net income
- -$45.86M
- EPS, diluted
- -$1.70
- Book value per share
- -$1.21
- Diluted shares
- 29M
Trading
- Previous close
- $0.71
- Open
- $0.72
- Day's range
- $0.70 – $0.78
- Volume
- 66,301
- Average volume (20 days)
- 170,241
- Beta (5 years)
- 1.96
- 52-week range
- $0.56 – $2.55
- RSI (14 days)
- 37.0
- Volatility (1 year)
- 170.0%
- Relative volume
- 0.02×
- WACC
- 14.7%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CELU | S&P 500 | Difference | CELU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.9% | -2.4% | −49.4 pts | ||
| 3 months | +7.3% | -1.2% | +8.4 pts | ||
| Year to date | -32.3% | +12.3% | −44.6 pts | ||
| 1 year | -56.3% | +12.4% | −68.8 pts | ||
| 3 years | -65.7% | +78.8% | −144.5 pts | -30.0% | +21.4% |
| 5 years | -99.0% | +75.2% | −174.1 pts | -59.9% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Celularity filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- News
- News
- News
About Celularity
Pharmaceutical Preparations
Celularity is a biotechnology company developing cell therapy products and biobanking services. The company specializes in cellular medicine, utilizing proprietary technology rights and cellular biological materials to develop therapeutic treatments. Alongside cell therapy research and development, it conducts biobanking operations and related service activities. The business also enters into intellectual property agreements, licensing arrangements, and research-oriented contracts. Its customer base includes commercial clients, institutional research partners, and healthcare organizations utilizing its biobanking services and cellular products.
Company profile, executives and historyCelularity stock: common questions
What is Celularity's stock price?
CELU closed at $0.75 on Nov 11, 2026, up 5.63% on the day. Over the past 52 weeks it traded between $0.56 and $2.55.
What is Celularity's market cap?
Celularity was worth $24.37M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CELU's P/E ratio?
Celularity lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.70), so it has no meaningful P/E ratio.
How much revenue does Celularity make?
Celularity reported revenue of $18.67M for the twelve months to Jun 30, 2026, down 58.1% from a year earlier.
Does Celularity pay a dividend?
No. Celularity has not paid a cash dividend over the last twelve months.
How has CELU stock performed over the past year?
Including dividends, CELU returned -56.3% over the past year, against +12.4% for the S&P 500.
Who are Celularity's competitors?
Companies most similar to Celularity by business, industry and size include CAPR, PRQR, JAGX, EMMA, QURE.
See a number that looks wrong?